Rapport Therapeutics, Inc.
RAPP
$38.08
$0.842.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 67.16% | -- | -- | -- | -- |
| Gross Profit | 35.03% | -- | -- | -- | -- |
| SG&A Expenses | 36.73% | 37.03% | 51.02% | 82.36% | 118.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.80% | 50.62% | 48.14% | 63.47% | 93.56% |
| Operating Income | -31.31% | -50.62% | -48.14% | -63.47% | -93.56% |
| Income Before Tax | -34.60% | -42.37% | -36.00% | -40.15% | -55.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.60% | -42.37% | -35.99% | -40.14% | -55.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.60% | -42.37% | -35.99% | -40.14% | -55.34% |
| EBIT | -31.31% | -50.62% | -48.14% | -63.47% | -93.56% |
| EBITDA | -31.55% | -50.92% | -48.04% | -63.05% | -92.62% |
| EPS Basic | 24.64% | 79.31% | 87.24% | 90.52% | 88.18% |
| Normalized Basic EPS | 24.64% | 72.01% | 84.58% | 88.99% | 86.48% |
| EPS Diluted | 24.64% | 79.31% | 87.24% | 90.52% | 88.18% |
| Normalized Diluted EPS | 24.64% | 72.01% | 84.58% | 88.99% | 86.48% |
| Average Basic Shares Outstanding | 44.65% | 88.31% | 191.75% | 782.75% | 1,627.86% |
| Average Diluted Shares Outstanding | 44.65% | 88.31% | 191.75% | 782.75% | 1,627.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |